Biogen is a biotechnology company that focuses on developing therapies for neurological and neurodegenerative diseases.

Biogen

Amgen is a multinational biopharmaceutical company that focuses on the discovery, development, and delivery of innovative human therapeutics.

Amgen

Moderna is a biotechnology company that focuses on developing messenger RNA (mRNA) therapeutics and vaccines.

Moderna

Genentech is a biotechnology company that focuses on developing and manufacturing pharmaceutical products for the treatment of various diseases.

Genentech Inc

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It has been at the forefront of addressing some of the world’s greatest public health challenges for over 35 years.

Gilead Oncology

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.

Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Tango Therapeutics

Tmunity Therapeutics

Vaccitech

AlloVir

Corus Pharma

Allogene Therapeutics

Arcus Biosciences

Pardes Biosciences

Galapagos

Gritstone bio

Precision BioSciences

Hookipa Pharma

Venrock

Gilead Sciences

Gilead is the second-largest biotech employer in the Bay Area and has grown considerably over the last four years. In this piece, Chairman and Chief Executive Officer Daniel O'Day talks about the company’s evolution, philanthropic culture and commitment to the local community.

#GileadNews: We announced today that we're acquiring CymaBay Therapeutics, reinforcing our long-standing commitment to liver disease. We'll continue advancing a potential therapy for primary biliary cholangitis, a rare and chronic liver disease that impairs liver function and quality of life. Read the press release and important information: https://gilead.inc/48baEtP

We’re proud to be on the list of #AmericasMostJUST companies, and for being ranked #5 in our industry. We were recognized for our work helping to make the world a healthier place for all people while fulfilling our responsibilities as a good corporate citizen.

Read more here: https://gilead.inc/3SzbVFh

#JUST100

This year’s theme for National Black HIV/AIDS Awareness Day is “Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities.” We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black Health), a Gilead grantee, about how together, we can take action toward meaningful change. 
 
We commend Virginia and our many community partners for continuing to honor and advance the decades of progress that Black communities have made in #HIV.  
 
Learn more: https://gilead.inc/487PjBu

#NBHAAD

#GileadNews: Our Q4 and Full Year 2023 Financial Results are now available. Read the press release: https://gilead.inc/3HNMQl9

#earnings

We know that there can only be true progress in scientific innovation when it's accessible to those who need it most. That's why we're working to address disparities in care for people around the world.
  
#WorldCancerDay | #CloseTheCareGap

For many people living with #cancer, hearing about the experiences of others can be helpful. Dale, who is living with #breastcancer, shares her journey and point of view about how sharing information can help reduce health disparities. 

#WorldCancerDay | #CloseTheCareGap

#GileadNews: Ted W. Love, MD joins Gilead Sciences’ Board of Directors. https://gilead.inc/3UoE04A

We're committed to amplifying Black voices and inspiring an inclusive culture that drives innovation. Learn more about inclusion and diversity at Gilead. https://gilead.inc/3UguIrw

#BlackHistoryMonth | #BHM | #GileadLife

We embed Environmental, Social and Governance (ESG) criteria into our value chain and core business operations to drive value for the communities we serve. In partnership with Reuters, we’ve developed a white paper on how purpose-driven ESG integration can address unmet needs, ensure health equity and promote a holistic approach to healthcare.

Reuters Events Sustainable Business #ESG

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

NASDAQ:GILD

Gilead Sciences, Inc.

Last Close

76.51

26/07 20:00

Market Cap

85.65B

Beta: 0.40

Volume Today

7.45M

Avg: 5.58M

PE Ratio

16.30

PFCF: 11.99

Dividend Yield

3.91%

Payout:48.14%